Chairman of the Board
Claudio Nessi has a 15 years experience in venture capital, investing in healthcare both in Europe and the US. Claudio has been an investor and board member of some very successful life science companies including Axovan AG, Endosense SA, PregLem SA and EUSA Pharma and currently serves on the board of directors of Arsanis, Inc. and Creabilis SA.
Claudio Nessi joined NeoMed Management in 2001 before becoming a Partner in 2004, and he heads NeoMed’s operation in Switzerland. Previously, Claudio was a Venture Partner with Genevest Consulting Group SA, Geneva. He has academic research experience in molecular biology from the Max Planck Institute and the University of Connecticut, and has published articles in leading scientific journals.
Claudio Nessi holds an MBA from Erasmus University, the Netherlands, and a Ph.D. in Genetics from the University of Pavia, Italy.
Ilias (Elias) Papatheodorou
Mr. Elias Papatheodorou brings with him more than 20 years of experience with private and public biotechnology companies, as well as with The Coca-Cola Company and Philip Morris International. As Chief Business Officer of Covagen AG, he was instrumental in the closing of a CHF46 million series B round and the subsequent acquisition of Covagen by Jannsen Pharmaceuticals, a J&J Company. Previously, Elias was Senior Vice President for Operations and Business Development at Medigene AG. Elias has also served for a number of years as the CEO of novosom AG. During his tenure, the Smarticles technology entered clinical trials in the U.S.A., the company raised funds and closed licensing deals. Finally, he engineered the sale of Novosom's assets to Marina Biotech (MRNA). He received his undergraduate education at Ithaca College, NY, and his graduate education at Cornell University, NY.
Eclosion 2 & Cie SCPC, represented by Jesus Martin Garcia
Jesús started his career at the World Economic Foundation and then at McKinsey & Co. focusing on pharma and food industries. In 1992, Jesús chose the entrepreneurial path, backing the creation and investing seed capital in a number of start-ups, such as Silverwire and VTX. He was the co-founder of LeShop, Switzerland’s largest and most successful e-commerce company. His entrepreneurial drive led to the launch of the Eclosion platform in 2004, to translate breakthrough science into life-altering drugs. This platform is a unique structure, with Eclosion2 investing from seed to clinical trials in companies, such as Genkyotex, which were created through the incubator Eclosion SA.
Jesús has an MS in Economics and a Master’s in Law from University of Geneva, and an MBA from Harvard Business School. He sits on the Board of the Harvard Business School Health Alumni Association and chairs the Boards of GeNeuro and ArisGen
Edmond de Rothschild Investment Partners, represented by Monsieur Gilles Nobécourt
Gilles has been a Partner at Edmond de Rothschild Investment Partners since 2002. Prior to this, he worked as a consultant dedicated to pharmaceutical and biotechnology companies for Russell Reynolds & Associates. In 1988, Gilles started at Rhône-Poulenc Group as Vice President, Public Affairs. In 1992, he was appointed Vice President, assistant to the Chairman and CEO of Rhône-Poulenc Rorer, the pharmaceutical affiliate of Rhône-Poulenc. He then became a founding member of RPR Gencell, the biotechnology division of Rhône-Poulenc Rorer. Initially General Manager for Europe, he subsequently became deputy General Manager of the Division based in San Francisco until 1999. He was then appointed General Manager of a commercial subsidiary in Mexico City. Before he started at Rhône-Poulenc, he was a Field Officer for the United Nations High Commissioner for Refugees in Africa and Central America, advisor to the French Prime Minister (1984-1986), advisor to the French Minister for Industry and Research (1983), Chief of Staff to the President of Languedoc Roussillon Regional Council (1982) and Social Advisor in the French Senate (1981-1982). Gilles graduated from the Paris Institute for Political Sciences (‘Sciences Po Paris’) in 1980, holds also a Master degree in applied economics and a certificate from the Stanford Global School of Business.
Catherine Moukheidir has 20 years of experience in finance including 15 in the biotechnology industry, holding multiple leadership roles and Board roles. At Innate Pharma, where she is a member of the Executive Board, she was responsible for a major financial restructuring. Prior to joining Innate, Mrs Moukheibir was CFO of Movetis, a Belgian biotech company (from 2008 to 2010), for which she led the IPO on Euronext Brussels and then the acquisition by Shire. Previously, she was Director Capital Markets at Zeltia (from 2001 to 2007), a Spanish biopharma and consumer chemicals group, where she steered its financial strategy. Before joining Zeltia, she was a management consultant and then worked as an Executive Director for two major Investment Banks: Salomon Smith Barney and Morgan Stanley.
Mary is co-founder and Senior Managing Director at the consultancy firm Evolution Life Sciences Partners LLC, specializing in strategic and financial advice for companies operating in life sciences and health care. Based in New York, Mary has held various positions at world-class investment banks such as Lehman Brothers Inc, Bear Stearns & Co, and Peter J Solomon. Mary has over 25 years of experience in health-related industries. She has developed strong expertise in the pharmaceutical, biotechnology, diagnostic, medical devices, and healthcare sectors.
She is a member of the board of directors of Lineagen Inc, a molecular diagnostics company, and sits on the Board of Deans of Yale School of Medicine and on the Advisory Board of Yale School of Management.
Mary received a B.A. from Harvard University. An American native, she is also fluent in French.
Stéphane is a founding partner of Vesalius Biocapital. Since 2007, he has invested in more than 15 biotech companies. Prior to founding Vesalius Biocapital, Stéphane was active as a venture coach for early-stage companies. He was a founder and managing partner at Value4Growth, a specialized Life Science consulting firm, supporting start-up companies in all aspects of company formation, product strategy and fund raising. He started his career with Arthur Andersen as an information technology auditor. After having led the mergers and acquisitions division of Arthur Andersen in Belgium from 1989 to 1995, he founded and led Arthur Andersen’s business consulting division in Belgium and Luxembourg. He served on the European Board of Partners of Arthur Andersen. Stéphane has an MBA and a degree in commercial engineering from the Catholic University of Leuven (Belgium).
Joseph McCracken, PhD
Dr. McCracken has over more than 25 years of experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. Most recently he was Global Head for Business Development & Licensing at Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 10 years. He was also at one time Director of Business Development and Representative Director of Genentech Ltd., Genentech’s wholly owned subsidiary in Japan, and has also held the positions of President of Technology Licensing and Alliances at Aventis, and Vice President of Worldwide Business and Technology Development at Rhone-Poulenc Rorer S.A
Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University